GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mithra Pharmaceuticals SA (FRA:1TM) » Definitions » EV-to-EBITDA

Mithra Pharmaceuticals (FRA:1TM) EV-to-EBITDA : -150.38 (As of Apr. 28, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Mithra Pharmaceuticals EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Mithra Pharmaceuticals's enterprise value is €198.50 Mil. Mithra Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was €-1.32 Mil. Therefore, Mithra Pharmaceuticals's EV-to-EBITDA for today is -150.38.

The historical rank and industry rank for Mithra Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:

FRA:1TM' s EV-to-EBITDA Range Over the Past 10 Years
Min: -150.38   Med: -11.22   Max: 21.21
Current: -150.38

During the past 11 years, the highest EV-to-EBITDA of Mithra Pharmaceuticals was 21.21. The lowest was -150.38. And the median was -11.22.

FRA:1TM's EV-to-EBITDA is ranked worse than
100% of 708 companies
in the Drug Manufacturers industry
Industry Median: 14.19 vs FRA:1TM: -150.38

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-28), Mithra Pharmaceuticals's stock price is €0.1796. Mithra Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was €-1.410. Therefore, Mithra Pharmaceuticals's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Mithra Pharmaceuticals EV-to-EBITDA Historical Data

The historical data trend for Mithra Pharmaceuticals's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mithra Pharmaceuticals EV-to-EBITDA Chart

Mithra Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -22.88 -47.28 -9.11 -10.51 22.44

Mithra Pharmaceuticals Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -10.51 - 22.44 -

Competitive Comparison of Mithra Pharmaceuticals's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Mithra Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mithra Pharmaceuticals's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mithra Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Mithra Pharmaceuticals's EV-to-EBITDA falls into.



Mithra Pharmaceuticals EV-to-EBITDA Calculation

Mithra Pharmaceuticals's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=198.500/-1.32
=-150.38

Mithra Pharmaceuticals's current Enterprise Value is €198.50 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Mithra Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was €-1.32 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mithra Pharmaceuticals  (FRA:1TM) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Mithra Pharmaceuticals's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.1796/-1.410
=At Loss

Mithra Pharmaceuticals's share price for today is €0.1796.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Mithra Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was €-1.410.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Mithra Pharmaceuticals EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Mithra Pharmaceuticals's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Mithra Pharmaceuticals (FRA:1TM) Business Description

Traded in Other Exchanges
Address
Rue Saint-Georges 5, Liege, BEL, 4000
Mithra Pharmaceuticals SA develops products for women's health with a particular focus on fertility, contraception, and menopause. It operates in three segments: Product Sales, Out-licensing, and Other. The company also develops and markets complex therapeutic solutions and offers partners a complete spectrum of research, development, and specialist manufacturing at its Mithra CDMO. Its geographical segments are Belgium, Europe and Outside Europe.

Mithra Pharmaceuticals (FRA:1TM) Headlines

No Headlines